TScan Therapeutics’ (TCRX) Buy Rating Reiterated at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They presently have a $9.00 target price on the stock.

A number of other equities analysts have also weighed in on the stock. Barclays dropped their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Wedbush reiterated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Morgan Stanley restated an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research report on Friday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research report on Thursday, March 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $9.33.

TScan Therapeutics Trading Up 14.5 %

NASDAQ:TCRX opened at $1.26 on Tuesday. The firm has a market capitalization of $71.30 million, a price-to-earnings ratio of -1.19 and a beta of 1.09. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The business has a fifty day moving average price of $1.90 and a 200-day moving average price of $3.38. TScan Therapeutics has a one year low of $1.06 and a one year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Sell-side analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new position in TScan Therapeutics during the 4th quarter valued at approximately $32,000. Prudential Financial Inc. purchased a new position in shares of TScan Therapeutics in the fourth quarter valued at $32,000. ProShare Advisors LLC bought a new stake in TScan Therapeutics in the fourth quarter worth $40,000. Wells Fargo & Company MN raised its stake in TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after purchasing an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in TScan Therapeutics during the fourth quarter valued at $59,000. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.